Early-Stage Investment Competition

Precision Quantomics is developing a smarter approach to drug development to help address the nearly 90% failure rate across drug candidates. Using an integrated in silico and advanced lab tools platform, the company delivers insights that help biopharma teams make better decisions earlier in development. Its capabilities span quantitative proteomics, biological reagents, and predictive in vitro testing to improve confidence in safety, metabolism, and translational relevance before costly late-stage setbacks occur. By combining computational and experimental strengths, Precision Quantomics aims to reduce time, cost, and risk while improving the likelihood of clinical success.